Literature DB >> 30004110

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.

Louis Drevon1, Alice Marceau2, Odile Maarek1, Wendy Cuccuini1, Emmanuelle Clappier1, Virginie Eclache3, Thomas Cluzeau4, Valentine Richez4, Inès Berkaoui4, Sophie Dimicoli-Salazar5, Audrey Bidet5, Jean-Philippe Vial5, Sophie Park6, Christina Vieira Dos Santos6, Eléonore Kaphan6, Céline Berthon2, Aspasia Stamatoullas7, François Delhommeau8, Nassera Abermil8, Thorsten Braun3, Rosa Sapena9, Daniel Lusina3, Aline Renneville2, Lionel Adès1, Sophie Raynaud4, Pierre Fenaux1.   

Abstract

Isolated trisomy 8 (+8) is a frequent cytogenetic abnormality in the myelodysplastic syndromes (MDS), but its characteristics are poorly reported. We performed a retrospective study of 138 MDS patients with isolated +8, classified or reclassified as MDS (excluding MDS/myeloproliferative neoplasm). Myeloproliferative (MP) features were defined by the repeated presence of one of the following: white blood cell count >10 × 109 /l, myelemia (presence of circulating immature granulocytes with a predominance of more mature forms) >2%, palpable splenomegaly. Fifty-four patients (39·1%) had MP features: 28 at diagnosis, 26 were acquired during evolution. MP forms had more EZH2 (33·3% vs. 12·0% in non-MP, P = 0·047), ASXL1 (66·7% vs. 42·3%, P = 0·048) and STAG2 mutations (77·8% vs. 21·7%, P = 0·006). Median event-free survival (EFS) and overall survival (OS) were 25 and 27 months for patients with MP features at diagnosis, versus 28 (P = 0·15) and 39 months (P = 0·085) for those without MP features, respectively. Among the 57 patients who received hypomethylating agent (HMA), OS was lower in MP cases (13 months vs. 23 months in non-MP cases, P = 0.02). In conclusion, MP features are frequent in MDS with isolated +8. MP forms had more EZH2, ASXL1 and STAG2 mutations, responded poorly to HMA, and tended to have poorer survival than non-MP forms.
© 2018 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  myelodysplastic syndromes; myelodysplastic-myeloproliferative diseases; trisomy 8

Mesh:

Substances:

Year:  2018        PMID: 30004110     DOI: 10.1111/bjh.15490

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Reticulocytosis As a Whistleblower: A Rare Case of Acquired Elliptocytosis in a Myelodysplastic Syndrome Patient With Trisomy 8.

Authors:  Mehdi Hage-Sleiman; Jaja Zhu; Hippolyte Guérineau; Emily Ronez; Katayoun Jondeau; Olivier Kosmider; Véronique Picard; Maha Denguir; Agathe Maillon; Sylvain Clauser; Valérie Bardet
Journal:  Hemasphere       Date:  2021-01-12

2.  Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes.

Authors:  Xuefen Yan; Lu Wang; Lingxu Jiang; Yingwan Luo; Peipei Lin; Wenli Yang; Yanling Ren; Liya Ma; Xinping Zhou; Chen Mei; Li Ye; Gaixiang Xu; Weilai Xu; Haiyang Yang; Chenxi Lu; Jie Jin; Hongyan Tong
Journal:  Cancer Med       Date:  2021-02-20       Impact factor: 4.452

3.  Myelodysplastic syndrome transforming to atypical chronic myeloid leukemia shows changes in its mutation allele frequency and acquisition of new mutations.

Authors:  Hakim Nm; Tam W; Philipovskiy A; Tonk V; Orazi A
Journal:  Leuk Res Rep       Date:  2021-05-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.